Free Trial
NASDAQ:PRFX

PainReform Q4 2025 Earnings Results & Report

PainReform logo
$0.69 -0.09 (-11.83%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PainReform reported Q4 2025 earnings on March 26, 2026. The company reported EPS of -$1.01.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

PainReform EPS Results

Actual EPS
-$1.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

PainReform Q4 2025 Earnings FAQ

PainReform (NASDAQ:PRFX) reported earnings of -$1.01 per share for Q4 2025. The report was announced on Thursday, March 26, 2026.

PainReform Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX) (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s work is aimed at addressing pain experienced after surgical procedures and reducing reliance on conventional short-acting analgesics.

PainReform’s lead product candidate, PRF-110, is an extended-release formulation of ropivacaine, a local anesthetic. Designed for administration at the surgical site, PRF-110 is intended to provide prolonged pain relief during the days following surgery. The company has evaluated the product in clinical programs involving procedures such as bunionectomy and hernia repair.

Founded in Israel, PainReform has conducted its product development activities through clinical and regulatory programs targeting the U.S. market. As a development-stage company, its business remains centered on advancing PRF-110 and its drug-delivery technology rather than marketing an established portfolio of commercial products.

View PainReform Profile